What's new

Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Withdrawn

Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Withdrawn

Jun 4, 2025 - 15:00
 0
Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Withdrawn
Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Withdrawn
Read More

Tags:

Previous Article

CHMP opinions on consultation procedures

Next Article

Human medicines European public assessment report (EPAR): Roclanda, latanoprost ...

Related Posts

EMA workshop on primary efficacy endpoints for antivirals and mAbs intended for the treatment of COVID-19 and Influenza, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 12, 2025  0

Minutes of the PRAC meeting 07-10 April 2025

Jun 4, 2025  0

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 2, 2025  0